Pub Date : 2024-03-08DOI: 10.1515/oncologie-2024-0040
Valentina Zagardo, Mandara M. Harikar, G. Ferini
Historically, radiation therapy has been devoted to the achievement of local control both in early and advanced disease, palliation of symptoms (i.e. pain), and the treatment of cancer complications (i.e. bone fractures, bleeding) in advanced/metastatic cancer. Recently, the discovery of the role of radiation therapy as a trigger to activate the immune system has led to an increased interest among insiders regarding the interaction between radiation therapy and host immune reactions. The immune systemic effects of radiation therapy are widely acknowledged to be both immunosuppressive and immunostimulant, albeit there exists considerable uncertainty regarding the doses/fraction that can induce them. The main aim of this brief paper is to describe the systemic anti-tumor responses following radiation therapy on the basis of selected doses/fraction.
{"title":"Is an immune-oriented use of radiation therapy possible? An increasingly open question under the spotlight of immunotherapy","authors":"Valentina Zagardo, Mandara M. Harikar, G. Ferini","doi":"10.1515/oncologie-2024-0040","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0040","url":null,"abstract":"\u0000 Historically, radiation therapy has been devoted to the achievement of local control both in early and advanced disease, palliation of symptoms (i.e. pain), and the treatment of cancer complications (i.e. bone fractures, bleeding) in advanced/metastatic cancer. Recently, the discovery of the role of radiation therapy as a trigger to activate the immune system has led to an increased interest among insiders regarding the interaction between radiation therapy and host immune reactions. The immune systemic effects of radiation therapy are widely acknowledged to be both immunosuppressive and immunostimulant, albeit there exists considerable uncertainty regarding the doses/fraction that can induce them. The main aim of this brief paper is to describe the systemic anti-tumor responses following radiation therapy on the basis of selected doses/fraction.","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140257828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-07DOI: 10.1515/oncologie-2023-0417
Jinzhu Feng, Jie Zhang, Yong Chen
Osteosarcoma stands as a highly aggressive primary bone malignancy with a notable penchant for metastasis and a grim prognosis. The exploration of metabolic gene signatures, particularly those involved in glycolysis and cholesterol synthesis, has recently garnered attention for their potential to predict cancer progression and therapeutic outcomes. This study probes the prognostic value of a glycolysis and cholesterol synthesis-related gene signature (GCSRG) in osteosarcoma, along with its influence on the tumor immune microenvironment. A comprehensive bioinformatics approach was applied to osteosarcoma samples from the TCGA database, incorporating unsupervised clustering to delineate patient subsets, differential gene expression analysis to identify key metabolic pathways, and survival analysis to ascertain prognostic validity. The investigation yielded a distinct GCSRG with significant prognostic capabilities. Notably, a high GCSRG score correlated with worse patient outcomes but revealed a marked enrichment in immune cell infiltration within the tumor milieu, suggesting a complex relationship between metabolism and immune surveillance in osteosarcoma. The GCSRG emerges as a promising biomarker for osteosarcoma prognosis, offering new vistas for assessing patient suitability for immunotherapeutic interventions. The potential of the GCSRG to act as a guide for personalized treatment strategies is highlighted, underscoring the need for strategic therapeutic modulation based on metabolic and immune interactions to improve patient prognosis in osteosarcoma.
{"title":"Prognostic value of a glycolysis and cholesterol synthesis related gene signature in osteosarcoma: implications for immune microenvironment and personalized treatment strategies","authors":"Jinzhu Feng, Jie Zhang, Yong Chen","doi":"10.1515/oncologie-2023-0417","DOIUrl":"https://doi.org/10.1515/oncologie-2023-0417","url":null,"abstract":"\u0000 \u0000 \u0000 Osteosarcoma stands as a highly aggressive primary bone malignancy with a notable penchant for metastasis and a grim prognosis. The exploration of metabolic gene signatures, particularly those involved in glycolysis and cholesterol synthesis, has recently garnered attention for their potential to predict cancer progression and therapeutic outcomes. This study probes the prognostic value of a glycolysis and cholesterol synthesis-related gene signature (GCSRG) in osteosarcoma, along with its influence on the tumor immune microenvironment.\u0000 \u0000 \u0000 \u0000 A comprehensive bioinformatics approach was applied to osteosarcoma samples from the TCGA database, incorporating unsupervised clustering to delineate patient subsets, differential gene expression analysis to identify key metabolic pathways, and survival analysis to ascertain prognostic validity.\u0000 \u0000 \u0000 \u0000 The investigation yielded a distinct GCSRG with significant prognostic capabilities. Notably, a high GCSRG score correlated with worse patient outcomes but revealed a marked enrichment in immune cell infiltration within the tumor milieu, suggesting a complex relationship between metabolism and immune surveillance in osteosarcoma.\u0000 \u0000 \u0000 \u0000 The GCSRG emerges as a promising biomarker for osteosarcoma prognosis, offering new vistas for assessing patient suitability for immunotherapeutic interventions. The potential of the GCSRG to act as a guide for personalized treatment strategies is highlighted, underscoring the need for strategic therapeutic modulation based on metabolic and immune interactions to improve patient prognosis in osteosarcoma.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140258221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-29DOI: 10.1515/oncologie-2023-0560
Liye Hu, Zhongyuan Zhang, Yun Fu, Feng Zhu, Xin Li, Min Zou, Rui-Jun Yang
The impact of Schizandrin A (Sch A) on 5-fluorouracil (5-Fu) in gastric cancer (GC) cells is not yet understood, despite its known anticancer and multidrug resistance-reversing properties in various tumors. The objective of this study was to investigate the ability of Sch A to reverse resistance and evaluate its mechanisms in GC cells that are resistant to 5-Fu. 5-Fu-sensitive gastric cancer (GC) cells were subjected to treatment with 5-Fu, while 5-Fu-resistant GC cells AGS/5-Fu and SGC7901/5-Fu were successfully developed. In both in vitro and in vivo settings, the impact of Sch A alone or in combination with 5-Fu on tumor cell growth, proliferation, migration, invasion, and ferroptosis-related metabolism was examined by stimulating these cells. A number of additional experiments were conducted in an attempt to elucidate the molecular mechanism of increased ferroptosis. Findings from our research indicate that the utilization of Sch A alongside 5-Fu could potentially be beneficial in combating drug resistance and treating GC in a reverse manner. The coadministration of Sch A was demonstrated to inhibit metastasis and chemotherapy resistance in 5-Fu-resistant GC cells by promoting the initiation of ferroptosis, a type of cell death that relies on iron. This effect was also confirmed in a xenograft nude mouse model. Through a mechanistic approach, the combined administration of Sch A exhibited a synergistic effect on enhancing the expression of the transferrin receptor. Consequently, this led to the accumulation of iron within cells, triggering lipid peroxidation and ultimately causing the death of 5-Fu-resistant GC cells. In conclusion, the findings from this research have presented a new approach to enhancing GC chemosensitivity, suggesting Sch A as an innovative regulator of ferroptosis. Mechanistically, ferroptosis is induced by Sch A coadministration via increasing transferrin receptor expression.
尽管五味子甲素（Sch A）在多种肿瘤中具有已知的抗癌和多药耐药性逆转特性，但它对胃癌（GC）细胞中的 5-氟尿嘧啶（5-Fu）的影响尚不清楚。本研究的目的是调查 Sch A 在对 5-Fu 耐药的 GC 细胞中逆转耐药性的能力并评估其机制。 对5-Fu敏感的胃癌（GC）细胞接受了5-Fu治疗，而对5-Fu耐药的GC细胞AGS/5-Fu和SGC7901/5-Fu则被成功培育出来。在体外和体内环境中，通过刺激这些细胞，研究了 Sch A 单独或与 5-Fu 联合使用对肿瘤细胞生长、增殖、迁移、侵袭和铁蛋白相关代谢的影响。我们还进行了其他一些实验，试图阐明铁氧化作用增强的分子机制。 我们的研究结果表明，在使用 5-Fu 的同时使用 Sch A 有可能有益于对抗耐药性和反向治疗 GC。研究证明，联合使用 Sch A 可通过促进铁凋亡（一种依赖铁的细胞死亡类型）的启动，抑制 5-Fu 耐药性 GC 细胞的转移和化疗耐药性。这一效果在异种移植裸鼠模型中也得到了证实。通过机理研究，联合施用 Sch A 对增强转铁蛋白受体的表达有协同作用。因此，这导致铁在细胞内积累，引发脂质过氧化反应，最终导致耐 5-Fu GC 细胞死亡。 总之，这项研究的结果提出了一种增强 GC 化学敏感性的新方法，表明 Sch A 是一种创新的铁变态反应调节剂。从机理上讲，联合给药 Sch A 可通过增加转铁蛋白受体的表达来诱导铁变态反应。
{"title":"Schizandrin A enhances the sensitivity of gastric cancer cells to 5-FU by promoting ferroptosis","authors":"Liye Hu, Zhongyuan Zhang, Yun Fu, Feng Zhu, Xin Li, Min Zou, Rui-Jun Yang","doi":"10.1515/oncologie-2023-0560","DOIUrl":"https://doi.org/10.1515/oncologie-2023-0560","url":null,"abstract":"\u0000 \u0000 \u0000 The impact of Schizandrin A (Sch A) on 5-fluorouracil (5-Fu) in gastric cancer (GC) cells is not yet understood, despite its known anticancer and multidrug resistance-reversing properties in various tumors. The objective of this study was to investigate the ability of Sch A to reverse resistance and evaluate its mechanisms in GC cells that are resistant to 5-Fu.\u0000 \u0000 \u0000 \u0000 5-Fu-sensitive gastric cancer (GC) cells were subjected to treatment with 5-Fu, while 5-Fu-resistant GC cells AGS/5-Fu and SGC7901/5-Fu were successfully developed. In both in vitro and in vivo settings, the impact of Sch A alone or in combination with 5-Fu on tumor cell growth, proliferation, migration, invasion, and ferroptosis-related metabolism was examined by stimulating these cells. A number of additional experiments were conducted in an attempt to elucidate the molecular mechanism of increased ferroptosis.\u0000 \u0000 \u0000 \u0000 Findings from our research indicate that the utilization of Sch A alongside 5-Fu could potentially be beneficial in combating drug resistance and treating GC in a reverse manner. The coadministration of Sch A was demonstrated to inhibit metastasis and chemotherapy resistance in 5-Fu-resistant GC cells by promoting the initiation of ferroptosis, a type of cell death that relies on iron. This effect was also confirmed in a xenograft nude mouse model. Through a mechanistic approach, the combined administration of Sch A exhibited a synergistic effect on enhancing the expression of the transferrin receptor. Consequently, this led to the accumulation of iron within cells, triggering lipid peroxidation and ultimately causing the death of 5-Fu-resistant GC cells.\u0000 \u0000 \u0000 \u0000 In conclusion, the findings from this research have presented a new approach to enhancing GC chemosensitivity, suggesting Sch A as an innovative regulator of ferroptosis. Mechanistically, ferroptosis is induced by Sch A coadministration via increasing transferrin receptor expression.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140413707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The therapeutic effect against triple-negative breast cancer (TNBC) varies among individuals. Finding signatures to predict immune efficacy is particularly urgent. Considering the connection between the microenvironment and hypoxia, hypoxia-related signatures could be more effective. Therefore, in this study, we aimed sought to construct a hypoxia-immune-related prediction model for breast cancer and identify therapeutic targets. Immune and hypoxia status in the TNBC microenvironment were investigated using single-sample Gene Set Enrichment Analysis (ssGSEA) and Uniform Manifold Approximation and Projection (UMAP). The least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis were employed to build a prognostic model based on hypoxia-immune-related differentially expressed genes. The Cancer Genome Atlas (TCGA) cohort, real-time quantitative polymerase chain reaction (qRT-PCR), and immunofluorescence staining were utilized to analyze the expression differences. Tumor immune dysfunction and exclusion indexes were used to indicate the effect of immunotherapy. We identified 11 signatures related to hypoxia and immunity. Among these genes, C-X-C motif chemokine ligand (CXCL) 9, 10, and 11 were up-regulated in TNBC tissues compared to normal tissues. Furthermore, CXCL9, 10, 11, and 13 were found to enhance the effect of immunotherapy. These findings suggest the value of the hypoxia-immune-related prognostic model for estimating the risk in patients with TNBC, and CXCL9, 10, 11, and 13 are potential targets to overcome immune resistance in TNBC.
{"title":"Identification of hypoxia-immune-related signatures for predicting immune efficacy in triple-negative breast cancer","authors":"Luping Wang, Haote Han, Jiahui Ma, Yue Feng, Zhuo Han, Vinesh J Maharaj, Jingkui Tian, Wei Zhu, Shouxin Li, Xiying Shao","doi":"10.1515/oncologie-2023-0539","DOIUrl":"https://doi.org/10.1515/oncologie-2023-0539","url":null,"abstract":"\u0000 \u0000 \u0000 The therapeutic effect against triple-negative breast cancer (TNBC) varies among individuals. Finding signatures to predict immune efficacy is particularly urgent. Considering the connection between the microenvironment and hypoxia, hypoxia-related signatures could be more effective. Therefore, in this study, we aimed sought to construct a hypoxia-immune-related prediction model for breast cancer and identify therapeutic targets.\u0000 \u0000 \u0000 \u0000 Immune and hypoxia status in the TNBC microenvironment were investigated using single-sample Gene Set Enrichment Analysis (ssGSEA) and Uniform Manifold Approximation and Projection (UMAP). The least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis were employed to build a prognostic model based on hypoxia-immune-related differentially expressed genes. The Cancer Genome Atlas (TCGA) cohort, real-time quantitative polymerase chain reaction (qRT-PCR), and immunofluorescence staining were utilized to analyze the expression differences. Tumor immune dysfunction and exclusion indexes were used to indicate the effect of immunotherapy.\u0000 \u0000 \u0000 \u0000 We identified 11 signatures related to hypoxia and immunity. Among these genes, C-X-C motif chemokine ligand (CXCL) 9, 10, and 11 were up-regulated in TNBC tissues compared to normal tissues. Furthermore, CXCL9, 10, 11, and 13 were found to enhance the effect of immunotherapy.\u0000 \u0000 \u0000 \u0000 These findings suggest the value of the hypoxia-immune-related prognostic model for estimating the risk in patients with TNBC, and CXCL9, 10, 11, and 13 are potential targets to overcome immune resistance in TNBC.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140417754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-26DOI: 10.1515/oncologie-2023-0556
Phuong Cam Pham, Thai Van Pham, Long Doan Dinh, Loi Thuan Nguyen, Nam Viet Le, Mai Bich Bui, Hung Quang Nguyen, Tuyen Van Pham, Quynh Thuy Thi Vo, Thu Binh Vu, Hien Thu Thi Vu, Ngoc Bich Thi Le, Binh Quoc Hoang, Anh Lan Thi Luong, Hoai Thi Nguyen, Ly Phuong Thi Nguyen, Lanh Minh Pham, Thuy Phuong Ngo, Hien Minh Nguyen, Dang Ngoc Tran, Vien Truong Nguyen, Khoa Trong Mai
Prostate cancer features have been linked to mutations in the BRCA1 and BRCA2 genes. Assessing the status of BRCA1 and BRCA2 gene carriers in patients contributes to accurate diagnosis, disease prognosis as well as appropriate targeted treatment methods. This study evaluated the prevalence of these mutations in Vietnamese prostate cancer patients and assessed their correlation with clinical features. A cross-sectional study was performed at Bach Mai Hospital between 2021 and 2022. We enrolled 60 prostate cancer patients. Next-generation gene sequencing was used to identify BRCA1 and BRCA2 mutations in formalin-fixed paraffin-embedded samples. Patients with somatic gene mutations underwent further germline mutation analysis. We also reported a case series following the British Medical Journal guidelines, detailing the clinical course of such patients. Patients with BRCA2 pathogenic variants revealed no BRCA1 mutations, although different mutations were identified. Two patients showed germline mutations. Patients with BRCA mutations were younger (average age: 66.2 years) than those with non-mutations (72.1 years) at diagnosis. High Gleason scores, lymph node metastases, and distant metastases were more prevalent in the mutation group. One patient with germline BRCA mutation had aggressive prostate cancer and early resistance to non-PARPi (Poly ADP-ribose polymerase inhibitors) treatments. We provide preliminary data on BRCA mutations in Vietnamese patients with prostate cancer, suggesting that BRCA2 mutations correlate with aggressive disease characteristics. Our findings further elucidate the clinical implications of these mutations.
{"title":"BRCA mutation in Vietnamese prostate cancer patients: a mixed cross-sectional study and case series","authors":"Phuong Cam Pham, Thai Van Pham, Long Doan Dinh, Loi Thuan Nguyen, Nam Viet Le, Mai Bich Bui, Hung Quang Nguyen, Tuyen Van Pham, Quynh Thuy Thi Vo, Thu Binh Vu, Hien Thu Thi Vu, Ngoc Bich Thi Le, Binh Quoc Hoang, Anh Lan Thi Luong, Hoai Thi Nguyen, Ly Phuong Thi Nguyen, Lanh Minh Pham, Thuy Phuong Ngo, Hien Minh Nguyen, Dang Ngoc Tran, Vien Truong Nguyen, Khoa Trong Mai","doi":"10.1515/oncologie-2023-0556","DOIUrl":"https://doi.org/10.1515/oncologie-2023-0556","url":null,"abstract":"\u0000 \u0000 \u0000 Prostate cancer features have been linked to mutations in the BRCA1 and BRCA2 genes. Assessing the status of BRCA1 and BRCA2 gene carriers in patients contributes to accurate diagnosis, disease prognosis as well as appropriate targeted treatment methods. This study evaluated the prevalence of these mutations in Vietnamese prostate cancer patients and assessed their correlation with clinical features.\u0000 \u0000 \u0000 \u0000 A cross-sectional study was performed at Bach Mai Hospital between 2021 and 2022. We enrolled 60 prostate cancer patients. Next-generation gene sequencing was used to identify BRCA1 and BRCA2 mutations in formalin-fixed paraffin-embedded samples. Patients with somatic gene mutations underwent further germline mutation analysis. We also reported a case series following the British Medical Journal guidelines, detailing the clinical course of such patients.\u0000 \u0000 \u0000 \u0000 Patients with BRCA2 pathogenic variants revealed no BRCA1 mutations, although different mutations were identified. Two patients showed germline mutations. Patients with BRCA mutations were younger (average age: 66.2 years) than those with non-mutations (72.1 years) at diagnosis. High Gleason scores, lymph node metastases, and distant metastases were more prevalent in the mutation group. One patient with germline BRCA mutation had aggressive prostate cancer and early resistance to non-PARPi (Poly ADP-ribose polymerase inhibitors) treatments.\u0000 \u0000 \u0000 \u0000 We provide preliminary data on BRCA mutations in Vietnamese patients with prostate cancer, suggesting that BRCA2 mutations correlate with aggressive disease characteristics. Our findings further elucidate the clinical implications of these mutations.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140429222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-23DOI: 10.1515/oncologie-2023-0530
Qiong He, Li Li
MicroRNA-302a (miR-302a) has been implicated in the oncogenic processes, but its role in hepatocellular carcinoma (HCC) chemoresistance and related mechanisms are still unclear. Therefore, the aim of this study was to investigate the role of miR-302a in HCC chemoresistance and elucidate its underlying mechanism. In this study, we detected the level of miR-302a in HCC tissues (including chemoresistant and chemosensitive tissues), non-tumor tissues, liver cancer cell lines, and 5-fluorouracil (5-FU)-resistant cells (HepG2/R). Additionally, we conducted cell viability, apoptosis, and autophagy analyses as well as assessed the levels of cleaved caspase-3, cleaved caspase-9, microtubule-associated protein 1 light chain 3 beta II (LC3B-II), Akt, and UNC-51 like kinase 1 (ULK1) in HepG2 cells transfected with miR-302a mimic or inhibitor prior to 5-FU treatment. Lastly, we predicted the target of miR-302a and verified the relationship between miR-302a and Akt by luciferase reporter and functional repair assays. Our results revealed that miR-302a was down-regulated in HCC tissues (p<0.01), especially in chemoresistant tissues (p<0.01). Consistently, the miR-302a level exhibited a lower expression in HepG2/R cells compared to their parental cells (p<0.01). Furthermore, the 5-FU-induced apoptosis and autophagy of HepG2 cells were promoted by miR-302a over-expression and diminished by miR-302a inhibition (p<0.01). Target analysis revealed that miR-302a could directly target Akt. Moreover, miR-302a inhibited Akt expression and subsequently elevated ULK1 expression (p<0.01). Inhibition of ULK1 could abrogate the sensitization of overexpressed miR-302a to 5-FU in HepG2 cells (p<0.01). Altogether, our results demonstrate that the down-regulation of miR-302a promotes 5-FU resistance in HCC by attenuating the Akt/ULK1 axis-dependent autophagy and apoptosis.
{"title":"MicroRNA-302a enhances 5-fluorouracil sensitivity in HepG2 cells by increasing AKT/ULK1-dependent autophagy-mediated apoptosis","authors":"Qiong He, Li Li","doi":"10.1515/oncologie-2023-0530","DOIUrl":"https://doi.org/10.1515/oncologie-2023-0530","url":null,"abstract":"\u0000 \u0000 \u0000 MicroRNA-302a (miR-302a) has been implicated in the oncogenic processes, but its role in hepatocellular carcinoma (HCC) chemoresistance and related mechanisms are still unclear. Therefore, the aim of this study was to investigate the role of miR-302a in HCC chemoresistance and elucidate its underlying mechanism.\u0000 \u0000 \u0000 \u0000 In this study, we detected the level of miR-302a in HCC tissues (including chemoresistant and chemosensitive tissues), non-tumor tissues, liver cancer cell lines, and 5-fluorouracil (5-FU)-resistant cells (HepG2/R). Additionally, we conducted cell viability, apoptosis, and autophagy analyses as well as assessed the levels of cleaved caspase-3, cleaved caspase-9, microtubule-associated protein 1 light chain 3 beta II (LC3B-II), Akt, and UNC-51 like kinase 1 (ULK1) in HepG2 cells transfected with miR-302a mimic or inhibitor prior to 5-FU treatment. Lastly, we predicted the target of miR-302a and verified the relationship between miR-302a and Akt by luciferase reporter and functional repair assays.\u0000 \u0000 \u0000 \u0000 Our results revealed that miR-302a was down-regulated in HCC tissues (p<0.01), especially in chemoresistant tissues (p<0.01). Consistently, the miR-302a level exhibited a lower expression in HepG2/R cells compared to their parental cells (p<0.01). Furthermore, the 5-FU-induced apoptosis and autophagy of HepG2 cells were promoted by miR-302a over-expression and diminished by miR-302a inhibition (p<0.01). Target analysis revealed that miR-302a could directly target Akt. Moreover, miR-302a inhibited Akt expression and subsequently elevated ULK1 expression (p<0.01). Inhibition of ULK1 could abrogate the sensitization of overexpressed miR-302a to 5-FU in HepG2 cells (p<0.01).\u0000 \u0000 \u0000 \u0000 Altogether, our results demonstrate that the down-regulation of miR-302a promotes 5-FU resistance in HCC by attenuating the Akt/ULK1 axis-dependent autophagy and apoptosis.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140437077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-09DOI: 10.1515/oncologie-2023-0511
Xuzhe Fang, Weihong Tong, Sheng Wu, Zhengyong Zhu, Jin Zhu
The effectiveness of cancer immunization is largely dependent on the tumor’s microenvironment, especially the tumor immune microenvironment. Emerging studies say microbes exist in tumor cells and immune cells, suggesting that these microbes can affect the state of the immune microenvironment of the tumor. Our comprehensive review navigates the intricate nexus between intratumoral microorganisms and their role in tumor biology and immune modulation. Beginning with an exploration of the historical acknowledgment of microorganisms within tumors, the article underscores the evolution of the tumor microenvironment (TME) and its subsequent implications. Using findings from recent studies, we delve into the unique bacterial compositions across different tumor types and their influence on tumor growth, DNA damage, and immune regulation. Furthermore, we illuminate the potential therapeutic implications of targeting these intratumoral microorganisms, emphasizing their multifaceted roles from drug delivery agents to immunotherapy enhancers. As advancements in next-generation sequencing (NGS) technology redefine our understanding of the tumor microbiome, the article underscores the importance of discerning their precise role in tumor progression and tailoring therapeutic interventions. The review culminates by emphasizing ongoing challenges and the pressing need for further research to harness the potential of intratumoral microorganisms in cancer care.
{"title":"The role of intratumoral microorganisms in the progression and immunotherapeutic efficacy of head and neck cancer","authors":"Xuzhe Fang, Weihong Tong, Sheng Wu, Zhengyong Zhu, Jin Zhu","doi":"10.1515/oncologie-2023-0511","DOIUrl":"https://doi.org/10.1515/oncologie-2023-0511","url":null,"abstract":"\u0000 The effectiveness of cancer immunization is largely dependent on the tumor’s microenvironment, especially the tumor immune microenvironment. Emerging studies say microbes exist in tumor cells and immune cells, suggesting that these microbes can affect the state of the immune microenvironment of the tumor. Our comprehensive review navigates the intricate nexus between intratumoral microorganisms and their role in tumor biology and immune modulation. Beginning with an exploration of the historical acknowledgment of microorganisms within tumors, the article underscores the evolution of the tumor microenvironment (TME) and its subsequent implications. Using findings from recent studies, we delve into the unique bacterial compositions across different tumor types and their influence on tumor growth, DNA damage, and immune regulation. Furthermore, we illuminate the potential therapeutic implications of targeting these intratumoral microorganisms, emphasizing their multifaceted roles from drug delivery agents to immunotherapy enhancers. As advancements in next-generation sequencing (NGS) technology redefine our understanding of the tumor microbiome, the article underscores the importance of discerning their precise role in tumor progression and tailoring therapeutic interventions. The review culminates by emphasizing ongoing challenges and the pressing need for further research to harness the potential of intratumoral microorganisms in cancer care.","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139849133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-09DOI: 10.1515/oncologie-2023-0511
Xuzhe Fang, Weihong Tong, Sheng Wu, Zhengyong Zhu, Jin Zhu
The effectiveness of cancer immunization is largely dependent on the tumor’s microenvironment, especially the tumor immune microenvironment. Emerging studies say microbes exist in tumor cells and immune cells, suggesting that these microbes can affect the state of the immune microenvironment of the tumor. Our comprehensive review navigates the intricate nexus between intratumoral microorganisms and their role in tumor biology and immune modulation. Beginning with an exploration of the historical acknowledgment of microorganisms within tumors, the article underscores the evolution of the tumor microenvironment (TME) and its subsequent implications. Using findings from recent studies, we delve into the unique bacterial compositions across different tumor types and their influence on tumor growth, DNA damage, and immune regulation. Furthermore, we illuminate the potential therapeutic implications of targeting these intratumoral microorganisms, emphasizing their multifaceted roles from drug delivery agents to immunotherapy enhancers. As advancements in next-generation sequencing (NGS) technology redefine our understanding of the tumor microbiome, the article underscores the importance of discerning their precise role in tumor progression and tailoring therapeutic interventions. The review culminates by emphasizing ongoing challenges and the pressing need for further research to harness the potential of intratumoral microorganisms in cancer care.
{"title":"The role of intratumoral microorganisms in the progression and immunotherapeutic efficacy of head and neck cancer","authors":"Xuzhe Fang, Weihong Tong, Sheng Wu, Zhengyong Zhu, Jin Zhu","doi":"10.1515/oncologie-2023-0511","DOIUrl":"https://doi.org/10.1515/oncologie-2023-0511","url":null,"abstract":"\u0000 The effectiveness of cancer immunization is largely dependent on the tumor’s microenvironment, especially the tumor immune microenvironment. Emerging studies say microbes exist in tumor cells and immune cells, suggesting that these microbes can affect the state of the immune microenvironment of the tumor. Our comprehensive review navigates the intricate nexus between intratumoral microorganisms and their role in tumor biology and immune modulation. Beginning with an exploration of the historical acknowledgment of microorganisms within tumors, the article underscores the evolution of the tumor microenvironment (TME) and its subsequent implications. Using findings from recent studies, we delve into the unique bacterial compositions across different tumor types and their influence on tumor growth, DNA damage, and immune regulation. Furthermore, we illuminate the potential therapeutic implications of targeting these intratumoral microorganisms, emphasizing their multifaceted roles from drug delivery agents to immunotherapy enhancers. As advancements in next-generation sequencing (NGS) technology redefine our understanding of the tumor microbiome, the article underscores the importance of discerning their precise role in tumor progression and tailoring therapeutic interventions. The review culminates by emphasizing ongoing challenges and the pressing need for further research to harness the potential of intratumoral microorganisms in cancer care.","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139789199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-06DOI: 10.1515/oncologie-2023-0483
Yuhong Fan, Jiayin Hu, Tao Li, Jingqin Fang
Paraganglioma (PGL) is a rare extra-adrenal neuroendocrine tumor, and intrapericardial PGL is extremely rare. We report a rare case of intrapericardial nonfunctional PGL, which may be used as a reference for further analysis. This article presents the case of a 65-year-old woman with a 2-year history of lower extremity pain. Ultrasound revealed a hypoechoic mass adjacent to the right atrium, compressing and narrowing the right atrium. Computed tomography (CT) showed a low-density mass with marked enhancement suggestive of a solitary fibrous tumor or a vasogenic tumor of pericardial origin. Cardiac magnetic resonance imaging (MRI) confirmed the location and provided a primary diagnosis of solitary fibrous tumor, hemangioma, or hemangiosarcoma. The patient eventually underwent pericardial tumor resection, and the diagnosis of PGL was confirmed by postoperative histopathology. Pathology is considered the gold standard for the diagnosis of PGL. Imaging examinations can provide valuable information for the diagnosis and management of intrapericardial PGL, and surgery remains the treatment of choice.
{"title":"Intrapericardial nonfunctional paraganglioma: a case report and literature review","authors":"Yuhong Fan, Jiayin Hu, Tao Li, Jingqin Fang","doi":"10.1515/oncologie-2023-0483","DOIUrl":"https://doi.org/10.1515/oncologie-2023-0483","url":null,"abstract":"\u0000 \u0000 \u0000 Paraganglioma (PGL) is a rare extra-adrenal neuroendocrine tumor, and intrapericardial PGL is extremely rare. We report a rare case of intrapericardial nonfunctional PGL, which may be used as a reference for further analysis.\u0000 \u0000 \u0000 \u0000 This article presents the case of a 65-year-old woman with a 2-year history of lower extremity pain. Ultrasound revealed a hypoechoic mass adjacent to the right atrium, compressing and narrowing the right atrium. Computed tomography (CT) showed a low-density mass with marked enhancement suggestive of a solitary fibrous tumor or a vasogenic tumor of pericardial origin. Cardiac magnetic resonance imaging (MRI) confirmed the location and provided a primary diagnosis of solitary fibrous tumor, hemangioma, or hemangiosarcoma. The patient eventually underwent pericardial tumor resection, and the diagnosis of PGL was confirmed by postoperative histopathology.\u0000 \u0000 \u0000 \u0000 Pathology is considered the gold standard for the diagnosis of PGL. Imaging examinations can provide valuable information for the diagnosis and management of intrapericardial PGL, and surgery remains the treatment of choice.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139861370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-06DOI: 10.1515/oncologie-2023-0483
Yuhong Fan, Jiayin Hu, Tao Li, Jingqin Fang
Paraganglioma (PGL) is a rare extra-adrenal neuroendocrine tumor, and intrapericardial PGL is extremely rare. We report a rare case of intrapericardial nonfunctional PGL, which may be used as a reference for further analysis. This article presents the case of a 65-year-old woman with a 2-year history of lower extremity pain. Ultrasound revealed a hypoechoic mass adjacent to the right atrium, compressing and narrowing the right atrium. Computed tomography (CT) showed a low-density mass with marked enhancement suggestive of a solitary fibrous tumor or a vasogenic tumor of pericardial origin. Cardiac magnetic resonance imaging (MRI) confirmed the location and provided a primary diagnosis of solitary fibrous tumor, hemangioma, or hemangiosarcoma. The patient eventually underwent pericardial tumor resection, and the diagnosis of PGL was confirmed by postoperative histopathology. Pathology is considered the gold standard for the diagnosis of PGL. Imaging examinations can provide valuable information for the diagnosis and management of intrapericardial PGL, and surgery remains the treatment of choice.
{"title":"Intrapericardial nonfunctional paraganglioma: a case report and literature review","authors":"Yuhong Fan, Jiayin Hu, Tao Li, Jingqin Fang","doi":"10.1515/oncologie-2023-0483","DOIUrl":"https://doi.org/10.1515/oncologie-2023-0483","url":null,"abstract":"\u0000 \u0000 \u0000 Paraganglioma (PGL) is a rare extra-adrenal neuroendocrine tumor, and intrapericardial PGL is extremely rare. We report a rare case of intrapericardial nonfunctional PGL, which may be used as a reference for further analysis.\u0000 \u0000 \u0000 \u0000 This article presents the case of a 65-year-old woman with a 2-year history of lower extremity pain. Ultrasound revealed a hypoechoic mass adjacent to the right atrium, compressing and narrowing the right atrium. Computed tomography (CT) showed a low-density mass with marked enhancement suggestive of a solitary fibrous tumor or a vasogenic tumor of pericardial origin. Cardiac magnetic resonance imaging (MRI) confirmed the location and provided a primary diagnosis of solitary fibrous tumor, hemangioma, or hemangiosarcoma. The patient eventually underwent pericardial tumor resection, and the diagnosis of PGL was confirmed by postoperative histopathology.\u0000 \u0000 \u0000 \u0000 Pathology is considered the gold standard for the diagnosis of PGL. Imaging examinations can provide valuable information for the diagnosis and management of intrapericardial PGL, and surgery remains the treatment of choice.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139801327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：